QUADRAMET Side Effects

6657119-4 | Atelectasis, Culture Urine Positive, Diarrhoea, Pyrexia, White Blood Cell Count Decreased
on Mar 11, 2010 Male patient from UNITED STATES , 74 years of age, weighting 211.2 lb, was diagnosed with prostate cancer metastatic and was treated with Quadramet (View Usage). Patient experienced the following unwanted or unexpected effects: atelectasis, culture urine positive, diarrhoea, pyrexia, white blood cell count decreased. Quadramet dosage: 1.0 Mci/kg, Intravenous. During the same period patient was treated with DOCETAXEL (3.5714 Mg/m2, 1 In 3 Weeks, Intravenous) (View Docetaxel Review and Docetaxel Label ), ZOLEDRONIC ACID (View Zoledronic Acid Review and Zoledronic Acid Label ), LUPRON (View Lupron Review and Lupron Label ), DECADRON (View Decadron Review and Decadron Label ), PREDNISONE TAB (View Prednisone Tab Review and Prednisone Tab Label ), OXYCODONE HCL (View Oxycodone Hcl Review and Oxycodone Hcl Label ), MELOXICAM (View Meloxicam Review and Meloxicam Label ), IBUPROFEN (View Ibuprofen Review and Ibuprofen Label ). Patient was hospitalized.

6597222-0 | Activities Of Daily Living Impaired, Blood Creatine Increased, Blood Glucose Increased, Carbohydrate Antigen 27.29 Increased, Eosinophil Percentage Increased, Haematocrit Decreased, Haemoglobin Decreased, Lymphocyte Percentage Decreased
Patient was taking Quadramet (View Usage). Patient had the following side effects: activities of daily living impaired, blood creatine increased, blood glucose increased, carbohydrate antigen 27.29 increased, eosinophil percentage increased, haematocrit decreased, haemoglobin decreased, lymphocyte percentage decreased on Jan 28, 2010 from UNITED STATES Additional patient health information: Female patient , 57 years of age, weighting 173.0 lb, was diagnosed with metastases to bone, nausea (What is nausea?), pain (What is pain?) and. Quadramet dosage: Intravenous. During the same period patient was treated with CYMBALTA (Enteric Coated, 1 Po Bid, Oral) (View Cymbalta Review and Cymbalta Label ), LORAZEPAM (1 Po Q4h Prn, Oral) (View Lorazepam Review and Lorazepam Label ), MORPHINE SULFATE (10 Mg/5 Ml; 15 Ml Po Q2-4h Prn, Oral) (View Morphine Sulfate Review and Morphine Sulfate Label ), AMBIEN CR, PO SOLID SR (ZOLPIDEM TARTRATE) (TABLETS) (View Ambien Cr, Po Solid Sr (zolpidem Tartrate) (tablets) Review and Ambien Cr, Po Solid Sr (zolpidem Tartrate) (tablets) Label ), AZOR, PO SOLID (AMLODIPINE) (TABLETS) (View Azor, Po Solid (amlodipine) (tablets) Review and Azor, Po Solid (amlodipine) (tablets) Label ), CALTRATE 600+D PLUS, PO SOLID (CALCITE D) (TABLETS) (View Caltrate 600+d Plus, Po Solid (calcite D) (tablets) Review and Caltrate 600+d Plus, Po Solid (calcite D) (tablets) Label ), FEMARA, PO SOLID (LETROZOLE) (TABLETS) (View Femara, Po Solid (letrozole) (tablets) Review and Femara, Po Solid (letrozole) (tablets) Label ).

6595771-2 | Blood Creatinine Increased, Blood Glucose Increased, Carbohydrate Antigen 27.29 Increased, Eosinophil Percentage Increased, Haemoglobin Decreased, Lymphocyte Percentage Decreased, Mean Platelet Volume Decreased
Adverse event was reported on Feb 05, 2010 by a Female patient taking Quadramet (View Usage) (Dosage: Intravenous) was diagnosed with bone pain, nausea (What is nausea?) and. Location: UNITED STATES , 57 years of age, weighting 173.0 lb, After Quadramet was administered, patient had the following side effects: blood creatinine increased, blood glucose increased, carbohydrate antigen 27.29 increased, eosinophil percentage increased, haemoglobin decreased, lymphocyte percentage decreased, mean platelet volume decreased. During the same period patient was treated with CYMBALTA (Enteric Coated, 1 Po Bid, Oral) (View Cymbalta Review and Cymbalta Label ), LORAZEPAM (1 Po Q4h Prn, Oral) (View Lorazepam Review and Lorazepam Label ), MORPHINE SULFATE (10 Mg/5 Ml; 15 Ml Po Q2-4h Prn, Oral) (View Morphine Sulfate Review and Morphine Sulfate Label ), MORPHINE SUL HYT (Sustained Action, 1 Po Q12h, Oral) (View Morphine Sul Hyt Review and Morphine Sul Hyt Label ), AMBIEN CR, PO SOLID SR (ZOLPIDEM TARTRATE)(TABLETS) (View Ambien Cr, Po Solid Sr (zolpidem Tartrate)(tablets) Review and Ambien Cr, Po Solid Sr (zolpidem Tartrate)(tablets) Label ), AZOR, PO SOLID (AMLODIPINE)(TABLETS) (View Azor, Po Solid (amlodipine)(tablets) Review and Azor, Po Solid (amlodipine)(tablets) Label ), CALTRATE 600+D PLUS, PO SOLID (CALCITE D)(TABLETS) (View Caltrate 600+d Plus, Po Solid (calcite D)(tablets) Review and Caltrate 600+d Plus, Po Solid (calcite D)(tablets) Label ), FEMARA, PO SOLID (LETROZOLE) (TABLETS) (View Femara, Po Solid (letrozole) (tablets) Review and Femara, Po Solid (letrozole) (tablets) Label ).

5951231-0 | Platelet Count Decreased
on Nov 12, 2008 Male patient from UNITED STATES , 56 years of age, weighting 149.0 lb, was diagnosed with prostate cancer (What is prostate cancer?) and was treated with Quadramet (View Usage). Patient experienced the following unwanted or unexpected effects: platelet count decreased. Quadramet dosage: 135 Mci Iv Injection. During the same period patient was treated with .. (View .. Review and .. Label ), ZOLADEX (View Zoladex Review and Zoladex Label ), CASODEX (View Casodex Review and Casodex Label ).


5877997-6 | Bloody Discharge, Body Temperature Increased, Disease Progression, Hydronephrosis, Hypotension, Lung Disorder, Lymphadenopathy, Mediastinal Disorder, Neutropenia
on Sep 09, 2008 Male patient from UNITED STATES , weighting 190.0 lb, was treated with Quadramet (View Usage). Patient had the following side effects: bloody discharge, body temperature increased, disease progression, hydronephrosis, hypotension, lung disorder, lymphadenopathy, mediastinal disorder, neutropenia. Quadramet dosage: 99.7 Mci. During the same period patient was treated with ZOMETA (25.3 Mg) (View Zometa Review and Zometa Label ), LUPRON + CASODEX (View Lupron + Casodex Review and Lupron + Casodex Label ), MITOXANTRONE + PREDNISONE (View Mitoxantrone + Prednisone Review and Mitoxantrone + Prednisone Label ). Patient was hospitalized.

5780028-X | No Adverse Event
Patient was taking Quadramet (View Usage). After Quadramet was administered, patient had the following side effects: no adverse event on Jan 28, 2008 from UNITED STATES Additional patient health information: Male patient , 65 years of age, was diagnosed with bone pain and. Quadramet dosage: .

5777411-5 | Asthenia, Dyskinesia, Toxic Encephalopathy
Adverse event was reported on Jun 06, 2008 by a Male patient taking Quadramet (View Usage) (Dosage: ) was diagnosed with bone pain and. Location: UNITED STATES , 70 years of age, Patient experienced the following unwanted or unexpected effects: asthenia, dyskinesia, toxic encephalopathy. Patient was hospitalized.

5535723-4 | Dehydration, Duodenal Ulcer, Obstruction Gastric, Reflux Oesophagitis, Urinary Tract Infection
on Dec 04, 2007 Male patient from UNITED STATES , weighting 132.3 lb, was treated with Quadramet (View Usage). Patient had the following side effects: dehydration, duodenal ulcer, obstruction gastric, reflux oesophagitis, urinary tract infection (What is urinary tract infection?). Quadramet dosage: Received Only One Dose Per The Protocol On 6/27/2007. During the same period patient was treated with VITAMIN D (2800 Iu Took 2800 Iu Total For This Course (400iu Per Day) But Started In May Of 2007 With Course 1) (View Vitamin D Review and Vitamin D Label ), ZOMETA (4 Mg) (View Zometa Review and Zometa Label ). Patient was hospitalized.

5483824-1 | Syncope
on Oct 09, 2007 Female patient from UNITED STATES , weighting 141.3 lb, was treated with Quadramet (View Usage). After Quadramet was administered, patient had the following side effects: syncope. Quadramet dosage: 69.5 Mg. During the same period patient was treated with ZOMETA (4 Mg) (View Zometa Review and Zometa Label ), CALCIUM (View Calcium Review and Calcium Label ), VITAMIN D (View Vitamin D Review and Vitamin D Label ), LEVOTHYROXINE SODIUM (View Levothyroxine Sodium Review and Levothyroxine Sodium Label ). Patient was hospitalized.

5352560-4 | Agitation, Burning Sensation, Dermatitis Allergic
Patient was taking Quadramet (View Usage). Patient experienced the following unwanted or unexpected effects: agitation, burning sensation, dermatitis allergic on Jan 09, 2007 from UNITED STATES Additional patient health information: Female patient , 57 years of age, weighting 99.21 lb, was diagnosed with palliative care (What is palliative care?) and. Quadramet dosage: 176 Gbq. During the same period patient was treated with MORPHINE (View Morphine Review and Morphine Label ), NEURONTIN (View Neurontin Review and Neurontin Label ), NEXIAM (ESOMEPRAZOLE) (View Nexiam (esomeprazole) Review and Nexiam (esomeprazole) Label ), VOLTAREN (View Voltaren Review and Voltaren Label ), SEROTONIN ANTAGONISTS (View Serotonin Antagonists Review and Serotonin Antagonists Label ). Patient was hospitalized.

5352524-0 | Metastases To Abdominal Cavity, Pain, Thrombocytopenia
Adverse event was reported on Dec 06, 2006 by a Male patient taking Quadramet (View Usage) (Dosage: 1 Mci/kg, 37mbq/kg 1 Dose, Intravenous) was diagnosed with metastases to bone and. Location: UNITED STATES , 78 years of age, Patient had the following side effects: metastases to abdominal cavity, pain (What is pain?), thrombocytopenia. During the same period patient was treated with TECHNETIUM TC 99M METHYLENE DIPHOSPHONATE (View Technetium Tc 99m Methylene Diphosphonate Review and Technetium Tc 99m Methylene Diphosphonate Label ).

5352517-3 | Musculoskeletal Pain, Pain In Extremity
on Sep 19, 2006 Male patient from UNITED STATES , 52 years of age, weighting 235.9 lb, was diagnosed with prostate cancer metastatic and was treated with Quadramet (View Usage). After Quadramet was administered, patient had the following side effects: musculoskeletal pain, pain in extremity. Quadramet dosage: 1.25 Mci/kg, 1 Dose, Intravenous. During the same period patient was treated with ZOLEDRONIC ACID (4 Mg, 1 Dose, Intravenous, 4 Mg, 1 Dose, Intravenous) (View Zoledronic Acid Review and Zoledronic Acid Label ), MS CONTIN (View Ms Contin Review and Ms Contin Label ), HYDROCODONE W/APAP (HYDROCODONE) (View Hydrocodone W/apap (hydrocodone) Review and Hydrocodone W/apap (hydrocodone) Label ), PROMETHAZINE (View Promethazine Review and Promethazine Label ), MULTIVITAMINS (RETINOL, PANTHENOL) (View Multivitamins (retinol, Panthenol) Review and Multivitamins (retinol, Panthenol) Label ), IBUPROFEN (View Ibuprofen Review and Ibuprofen Label ), KADIAN (View Kadian Review and Kadian Label ). Patient was hospitalized.

5352516-1 | Karnofsky Scale Worsened, Pain, Performance Status Decreased, Spinal Fracture
on Jul 04, 2006 Male patient from UNITED STATES , 66 years of age, weighting 180.8 lb, was treated with Quadramet (View Usage). Patient experienced the following unwanted or unexpected effects: karnofsky scale worsened, pain (What is pain?), performance status decreased, spinal fracture. Quadramet dosage: 3100 Mbq, 1 Dose, Injection. Patient was hospitalized.

5192131-6 | Thrombocytopenia
Patient was taking Quadramet (View Usage). Patient had the following side effects: thrombocytopenia on Dec 04, 2006 from SPAIN Additional patient health information: Male patient , 44 years of age, weighting 163.1 lb, . Quadramet dosage: Intravenous.

5179514-5 | Acute Pulmonary Oedema, Anxiety, Atrial Fibrillation, Blood Alkaline Phosphatase Increased, Blood Creatinine Increased, Blood Ph Decreased, Blood Pressure Increased, Blood Urea Increased
Adverse event was reported on Nov 13, 2006 by a Male patient taking Quadramet (View Usage) (Dosage: 2542 Mbq, 1 Dose, Intravenous) was diagnosed with prostate cancer (What is prostate cancer?) and. Location: UNITED KINGDOM , 76 years of age, weighting 151.5 lb, After Quadramet was administered, patient had the following side effects: acute pulmonary oedema, anxiety (What is anxiety?), atrial fibrillation (What is atrial fibrillation?), blood alkaline phosphatase increased, blood creatinine increased, blood ph decreased, blood pressure increased, blood urea increased. During the same period patient was treated with ADALAT (View Adalat Review and Adalat Label ), DIETHYLSTILBESTROL (View Diethylstilbestrol Review and Diethylstilbestrol Label ), OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ), AMLODIPINE (View Amlodipine Review and Amlodipine Label ), TRAMADOL HCL (View Tramadol Hcl Review and Tramadol Hcl Label ). Patient was hospitalized.

5150999-3 | Acute Pulmonary Oedema, Anxiety, Atrial Fibrillation, Blood Creatinine Increased, Blood Urea Increased, Cardiac Failure Congestive, Left Ventricular Failure, Metastases To Lung, Mitral Valve Incompetence
on Oct 25, 2006 Male patient from UNITED KINGDOM , 76 years of age, weighting 151.5 lb, was diagnosed with prostate cancer (What is prostate cancer?) and was treated with Quadramet (View Usage). Patient experienced the following unwanted or unexpected effects: acute pulmonary oedema, anxiety (What is anxiety?), atrial fibrillation (What is atrial fibrillation?), blood creatinine increased, blood urea increased, cardiac failure congestive, left ventricular failure, metastases to lung, mitral valve incompetence. Quadramet dosage: 2542 Mbq, 1 Dose, Intravenous. During the same period patient was treated with ADALAT (View Adalat Review and Adalat Label ), DIETHYLSTILBESTROL (View Diethylstilbestrol Review and Diethylstilbestrol Label ), OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ), AMLODIPINE (View Amlodipine Review and Amlodipine Label ), TRAMADOL HCL (View Tramadol Hcl Review and Tramadol Hcl Label ). Patient was hospitalized.

5102855-4 | Acute Left Ventricular Failure, Anxiety, Atrial Fibrillation, Blood Ph Decreased, Blood Pressure Increased, Cardiac Failure Congestive, Cardiomegaly, Chest Discomfort, Cough
on Aug 16, 2006 Male patient from UNITED KINGDOM , 76 years of age, weighting 151.5 lb, was diagnosed with prostate cancer (What is prostate cancer?) and was treated with Quadramet (View Usage). Patient had the following side effects: acute left ventricular failure, anxiety (What is anxiety?), atrial fibrillation (What is atrial fibrillation?), blood ph decreased, blood pressure increased, cardiac failure congestive, cardiomegaly, chest discomfort, cough. Quadramet dosage: 2542 Mbq, 1 Dose, Intravenous. During the same period patient was treated with ADALAT (View Adalat Review and Adalat Label ), DIETHYLSTILBESTROL (View Diethylstilbestrol Review and Diethylstilbestrol Label ), OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ), AMLODIPINE (View Amlodipine Review and Amlodipine Label ), TRAMADOL HCL (View Tramadol Hcl Review and Tramadol Hcl Label ). Patient was hospitalized.

5083016-4 | Acute Pulmonary Oedema, Anxiety, Atrial Fibrillation, Blood Pressure Increased, Cardiac Failure Congestive, Contrast Media Reaction, Extrasystoles, Left Ventricular Failure, Lung Consolidation
Patient was taking Quadramet (View Usage). After Quadramet was administered, patient had the following side effects: acute pulmonary oedema, anxiety (What is anxiety?), atrial fibrillation (What is atrial fibrillation?), blood pressure increased, cardiac failure congestive, contrast media reaction, extrasystoles, left ventricular failure, lung consolidation on Jul 25, 2006 from UNITED KINGDOM Additional patient health information: Male patient , 76 years of age, weighting 151.5 lb, was diagnosed with bone pain and. Quadramet dosage: 2542 Mbq, 1 Dose, Intravenous. During the same period patient was treated with ADALAT (View Adalat Review and Adalat Label ), DIETHYLSTILBESTROL (View Diethylstilbestrol Review and Diethylstilbestrol Label ), OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ), AMLODIPINE (View Amlodipine Review and Amlodipine Label ), TRAMADOL HCL (View Tramadol Hcl Review and Tramadol Hcl Label ). Patient was hospitalized.

5070234-4 | Acute Pulmonary Oedema, Atrial Fibrillation, Blood Pressure Systolic Increased, Myocardial Infarction
Adverse event was reported on Jul 13, 2006 by a Male patient taking Quadramet (View Usage) (Dosage: 2542 Mbq, 1 Dose, Intravenous) was diagnosed with prostate cancer (What is prostate cancer?) and. Location: UNITED KINGDOM , 76 years of age, weighting 151.5 lb, Patient experienced the following unwanted or unexpected effects: acute pulmonary oedema, atrial fibrillation (What is atrial fibrillation?), blood pressure systolic increased, myocardial infarction. During the same period patient was treated with ADALAT (View Adalat Review and Adalat Label ), ALBUTEROL SPIROS (View Albuterol Spiros Review and Albuterol Spiros Label ). Patient was hospitalized.

5062281-3 | Acute Pulmonary Oedema, Atrial Fibrillation, Myocardial Infarction
on Jul 07, 2006 Male patient from UNITED KINGDOM , 76 years of age, was diagnosed with prostate cancer (What is prostate cancer?) and was treated with Quadramet (View Usage). Patient had the following side effects: acute pulmonary oedema, atrial fibrillation (What is atrial fibrillation?), myocardial infarction. Quadramet dosage: 2542 Mbq, 1 Dose; Intravenous.

5037612-0 | Arthralgia, Difficulty In Walking
on Mar 08, 2006 Male patient from GERMANY , 55 years of age, weighting 176.4 lb, was diagnosed with metastases to bone and was treated with Quadramet (View Usage). After Quadramet was administered, patient had the following side effects: arthralgia, difficulty in walking. Quadramet dosage: 3.26 Bq, 1 Dose, Intraveous. During the same period patient was treated with OPIOIDS (View Opioids Review and Opioids Label ), NSAID'S (View Nsaid's Review and Nsaid's Label ). Patient was hospitalized.

5037608-9 | Cardio-respiratory Arrest
Patient was taking Quadramet (View Usage). Patient experienced the following unwanted or unexpected effects: cardio-respiratory arrest on Feb 10, 2006 from SPAIN Additional patient health information: Male patient , 61 years of age, weighting 143.3 lb, was diagnosed with metastatic pain and. Quadramet dosage: Injection.

5037606-5 | Pathological Fracture
Adverse event was reported on Feb 02, 2006 by a Male patient taking Quadramet (View Usage) (Dosage: 3145 Mbq, Intravenous) was diagnosed with prostate cancer metastatic and. Location: SPAIN , 71 years of age, weighting 191.8 lb, Patient had the following side effects: pathological fracture. Patient was hospitalized.

5037604-1 | Pathological Fracture
on Dec 21, 2005 Male patient from SPAIN , 71 years of age, weighting 191.8 lb, was treated with Quadramet (View Usage). After Quadramet was administered, patient had the following side effects: pathological fracture. Quadramet dosage: . Patient was hospitalized.

5012127-4 | Thrombocytopenia
on May 11, 2006 Male patient from SPAIN , 44 years of age, weighting 163.1 lb, was treated with Quadramet (View Usage). Patient experienced the following unwanted or unexpected effects: thrombocytopenia. Quadramet dosage: Intravenous.

4989817-2 | Blood Creatinine Increased, Haematuria, Haemoglobin Decreased, Metastases To Bone, Metastases To Lung, Pyelonephritis Acute, Renal Ischaemia, Thrombocytopenia, White Blood Cell Count Decreased
Patient was taking Quadramet (View Usage). Patient had the following side effects: blood creatinine increased, haematuria, haemoglobin decreased, metastases to bone, metastases to lung, pyelonephritis acute, renal ischaemia, thrombocytopenia, white blood cell count decreased on Mar 31, 2006 from SPAIN Additional patient health information: Male patient , 45 years of age, weighting 163.1 lb, . Quadramet dosage: 74 Ml, 1 Dose, Intravenous. During the same period patient was treated with DIAZEPAM (View Diazepam Review and Diazepam Label ), DEXAMETHASONE TAB (View Dexamethasone Tab Review and Dexamethasone Tab Label ), DIPYRONE TAB (View Dipyrone Tab Review and Dipyrone Tab Label ), MORPHINE SULFATE (View Morphine Sulfate Review and Morphine Sulfate Label ). Patient was hospitalized.

4952123-6 | Blood Creatinine Increased, Haematuria, Haemoglobin Decreased, Thrombocytopenia
Adverse event was reported on Mar 02, 2006 by a Male patient taking Quadramet (View Usage) (Dosage: 74 Ml 1 Intravenous) . Location: SPAIN , 45 years of age, weighting 163.1 lb, After Quadramet was administered, patient had the following side effects: blood creatinine increased, haematuria, haemoglobin decreased, thrombocytopenia. During the same period patient was treated with DIAZEPAM (View Diazepam Review and Diazepam Label ), DEXAMETHASONE TAB (View Dexamethasone Tab Review and Dexamethasone Tab Label ), DIPYRONE TAB (View Dipyrone Tab Review and Dipyrone Tab Label ), MORPHINE SULFATE (View Morphine Sulfate Review and Morphine Sulfate Label ). Patient was hospitalized.

4947020-6 | Blood Count Abnormal, Blood Creatinine Increased, Blood Urea Increased, Platelet Count Decreased, White Blood Cell Count Decreased
on Apr 20, 2003 Male patient from UNITED STATES , weighting 177.5 lb, was diagnosed with metastatic pain and was treated with Quadramet (View Usage). Patient experienced the following unwanted or unexpected effects: blood count abnormal, blood creatinine increased, blood urea increased, platelet count decreased, white blood cell count decreased. Quadramet dosage: 1 Mcl/kg *80.5 Kg), 1 Dose, Intravenous.

4909877-4 | Abdominal Pain, Obstruction, Renal Failure
on Jan 10, 2006 Male patient from UNITED STATES , 62 years of age, weighting 203.0 lb, was diagnosed with prostate cancer (What is prostate cancer?) and was treated with Quadramet (View Usage). Patient had the following side effects: abdominal pain (What is abdominal pain?), obstruction, renal failure. Quadramet dosage: 92.3 Mci. During the same period patient was treated with MORPHINE SULFATE (View Morphine Sulfate Review and Morphine Sulfate Label ). Patient was hospitalized.

4872006-X | Neutropenic Sepsis, Oxygen Saturation Decreased, Septic Shock, Thrombocytopenia
Patient was taking Quadramet (View Usage). After Quadramet was administered, patient had the following side effects: neutropenic sepsis, oxygen saturation decreased, septic shock, thrombocytopenia on Dec 22, 2005 from UNITED STATES Additional patient health information: Male patient , 75 years of age, weighting 133.0 lb, was diagnosed with prostate cancer (What is prostate cancer?) and. Quadramet dosage: 52.5 Mci. During the same period patient was treated with HYDROCHLOROTHIAZIDE (View Hydrochlorothiazide Review and Hydrochlorothiazide Label ), LOTREL (View Lotrel Review and Lotrel Label ), DIPHENOXYLATE (View Diphenoxylate Review and Diphenoxylate Label ), ATROPINE AND PHENERGAN (View Atropine And Phenergan Review and Atropine And Phenergan Label ), LEVAQUIN (View Levaquin Review and Levaquin Label ), IV HYDRATION WITH NORMAL SALINE (View Iv Hydration With Normal Saline Review and Iv Hydration With Normal Saline Label ), ZOSYN (View Zosyn Review and Zosyn Label ), FLAGYL (View Flagyl Review and Flagyl Label ). Patient was hospitalized.

4864241-1 | Back Pain, Nausea
Adverse event was reported on Dec 21, 2005 by a Male patient taking Quadramet (View Usage) (Dosage: 72.96 Mci Given Once) was diagnosed with bone pain, metastases to bone and. Location: UNITED STATES , 74 years of age, Patient experienced the following unwanted or unexpected effects: back pain (What is back pain?), nausea (What is nausea?). During the same period patient was treated with ASPIRIN (View Aspirin Review and Aspirin Label ), COLACE (View Colace Review and Colace Label ), ZETIA (View Zetia Review and Zetia Label ), DURAGESIC 100 (View Duragesic-100 Review and Duragesic-100 Label ), FUROSEMIDE (View Furosemide Review and Furosemide Label ), NEURONTIN (View Neurontin Review and Neurontin Label ), KYTRIL (View Kytril Review and Kytril Label ). Patient was hospitalized.

4864240-X | Anaesthetic Complication, Hypercapnia, Hypertension, Respiratory Failure
on Dec 21, 2005 Male patient from UNITED STATES , 74 years of age, was diagnosed with bone cancer metastatic, bone pain and was treated with Quadramet (View Usage). Patient had the following side effects: anaesthetic complication, hypercapnia, hypertension, respiratory failure. Quadramet dosage: 72.96 Mci Given Once. During the same period patient was treated with CORDARONE (View Cordarone Review and Cordarone Label ), ZETIA (View Zetia Review and Zetia Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), ZOCOR (View Zocor Review and Zocor Label ), FLOMAX (View Flomax Review and Flomax Label ), COLACE (View Colace Review and Colace Label ), NEURONTIN (View Neurontin Review and Neurontin Label ). Patient was hospitalized.

4799791-X | Bone Marrow Failure, Platelet Count Decreased, Pneumonia, Rash Erythematous
on Oct 12, 2005 Male patient from UNITED STATES , 75 years of age, weighting 160.0 lb, was diagnosed with prostate cancer metastatic and was treated with Quadramet (View Usage). After Quadramet was administered, patient had the following side effects: bone marrow failure, platelet count decreased, pneumonia (What is pneumonia?), rash erythematous. Quadramet dosage: .

4784660-1 | Bone Marrow Disorder, Myelofibrosis, Myeloid Metaplasia
Patient was taking Quadramet (View Usage). Patient experienced the following unwanted or unexpected effects: bone marrow disorder, myelofibrosis, myeloid metaplasia on Jun 23, 2005 from UNITED STATES Additional patient health information: Female patient , 72 years of age, weighting 174.2 lb, was diagnosed with breast cancer metastatic and. Quadramet dosage: . During the same period patient was treated with ZESTORETIC (View Zestoretic Review and Zestoretic Label ), METFORMIN (View Metformin Review and Metformin Label ), ACTOS (View Actos Review and Actos Label ), AREDIA (View Aredia Review and Aredia Label ), PROCHLORPERAZINE (View Prochlorperazine Review and Prochlorperazine Label ), GLYBURIDE (View Glyburide Review and Glyburide Label ), PERCOCET (View Percocet Review and Percocet Label ), TIMOLOL MALEATE (View Timolol Maleate Review and Timolol Maleate Label ). Patient was hospitalized.

4734226-4 | Activated Partial Thromboplastin Time Prolonged, Asthenia, Bladder Tamponade, Blood Lactate Dehydrogenase Increased, Blood Potassium Increased, Candidiasis, Cardiac Failure Congestive, Difficulty In Walking, Gait Disturbance
Adverse event was reported on Jul 15, 2004 by a Male patient taking Quadramet (View Usage) (Dosage: 18.5 Mbq, 1x/da, Intravenous) was diagnosed with metastases to bone and. Location: JAPAN , 54 years of age, weighting 130.7 lb, Patient had the following side effects: activated partial thromboplastin time prolonged, asthenia, bladder tamponade, blood lactate dehydrogenase increased, blood potassium increased, candidiasis, cardiac failure congestive, difficulty in walking, gait disturbance. During the same period patient was treated with CASODEX (View Casodex Review and Casodex Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), ZOLADEX (View Zoladex Review and Zoladex Label ), MOSCONTIN (MORPHINE SULFATE) (View Moscontin (morphine Sulfate) Review and Moscontin (morphine Sulfate) Label ), VOLTAREN (View Voltaren Review and Voltaren Label ), MORPHINE HYDROCHLORIDE (MIORPHINE HYDROCHLORIDE) (View Morphine Hydrochloride (miorphine Hydrochloride) Review and Morphine Hydrochloride (miorphine Hydrochloride) Label ), PURSENNID (SENNA LEAF) (View Pursennid (senna Leaf) Review and Pursennid (senna Leaf) Label ), LEVOFLOXACIN (View Levofloxacin Review and Levofloxacin Label ). Patient was hospitalized.

4734222-7 | Back Pain, Breast Cancer, Condition Aggravated, Disease Progression, Malignant Neoplasm Progression, Osteolysis
on Jun 15, 2004 Female patient from JAPAN , 53 years of age, weighting 101.4 lb, was diagnosed with breast cancer recurrent, metastases to bone and was treated with Quadramet (View Usage). After Quadramet was administered, patient had the following side effects: back pain (What is back pain?), breast cancer (What is breast cancer?), condition aggravated, disease progression, malignant neoplasm progression, osteolysis. Quadramet dosage: 1798.4 Mbq, 1 Dose, Intravenous. During the same period patient was treated with SOLETON (ZALTOPROFEN) (View Soleton (zaltoprofen) Review and Soleton (zaltoprofen) Label ). Patient was hospitalized.

4734221-5 | Back Pain, Breast Cancer, Condition Aggravated, Malignant Neoplasm Progression, Osteolysis
on May 26, 2004 Female patient from JAPAN , 53 years of age, weighting 101.4 lb, was diagnosed with breast cancer recurrent, metastases to bone and was treated with Quadramet (View Usage). Patient experienced the following unwanted or unexpected effects: back pain (What is back pain?), breast cancer (What is breast cancer?), condition aggravated, malignant neoplasm progression, osteolysis. Quadramet dosage: 1798.4 Mbq, 1 Dose, Intravenous. Patient was hospitalized.

4734216-1 | Cough, Dyspnoea, Hyperhidrosis, Nausea, Oxygen Saturation Decreased
Patient was taking Quadramet (View Usage). Patient had the following side effects: cough, dyspnoea, hyperhidrosis, nausea (What is nausea?), oxygen saturation decreased on Jun 02, 2004 from NETHERLANDS Additional patient health information: Male patient , 72 years of age, weighting 242.5 lb, was diagnosed with prostate cancer metastatic, pain (What is pain?) and. Quadramet dosage: See Image. During the same period patient was treated with ZOMETA (See Image) (View Zometa Review and Zometa Label ), MORPHINE (3o Mg, 2x/day, Oral) (View Morphine Review and Morphine Label ), TOLTERODINE TARTRATE (View Tolterodine Tartrate Review and Tolterodine Tartrate Label ). Patient was hospitalized.

4734214-8 | Cough, Dyspnoea, Hyperhidrosis, Nausea, Oxygen Saturation Decreased
Adverse event was reported on May 23, 2004 by a Male patient taking Quadramet (View Usage) (Dosage: Intravenous) was diagnosed with prostate cancer metastatic, pain (What is pain?) and. Location: NETHERLANDS , 72 years of age, weighting 242.5 lb, After Quadramet was administered, patient had the following side effects: cough, dyspnoea, hyperhidrosis, nausea (What is nausea?), oxygen saturation decreased. During the same period patient was treated with MORPHINE (30 Mg, 2xday, Oral) (View Morphine Review and Morphine Label ), TOLTERODINE TARTRATE (View Tolterodine Tartrate Review and Tolterodine Tartrate Label ), BETAHISTINE (BETAHISTINE) (View Betahistine (betahistine) Review and Betahistine (betahistine) Label ), ACENOCOUMAROL (ACENOCOUMAROL) (View Acenocoumarol (acenocoumarol) Review and Acenocoumarol (acenocoumarol) Label ), VENLAFAXINE HCL (View Venlafaxine Hcl Review and Venlafaxine Hcl Label ), FINASTERIDE (View Finasteride Review and Finasteride Label ), PANTOPRAZOLE SODIUM (View Pantoprazole Sodium Review and Pantoprazole Sodium Label ). Patient was hospitalized.

4734212-4 | Arthralgia, Back Pain, Condition Aggravated, Disease Progression, Dysstasia, Pain In Extremity
on Jun 15, 2004 Female patient from JAPAN , 50 years of age, weighting 116.8 lb, was diagnosed with breast cancer recurrent, metastases to bone and was treated with Quadramet (View Usage). Patient experienced the following unwanted or unexpected effects: arthralgia, back pain (What is back pain?), condition aggravated, disease progression, dysstasia, pain in extremity. Quadramet dosage: 2170 Mbq, 1x/day, Intravenous. Patient was hospitalized.

4734210-0 | Arthralgia, Back Pain, Condition Aggravated, Disease Progression, Dysstasia, Pain In Extremity
on May 26, 2004 Female patient from JAPAN , 50 years of age, weighting 116.8 lb, was diagnosed with breast cancer recurrent, metastases to bone and was treated with Quadramet (View Usage). Patient had the following side effects: arthralgia, back pain (What is back pain?), condition aggravated, disease progression, dysstasia, pain in extremity. Quadramet dosage: 2170 Mbq, 1xday, Intravenous. Patient was hospitalized.

4734208-2 | Arthralgia, Dysstasia, Pain, Pain In Extremity
Patient was taking Quadramet (View Usage). After Quadramet was administered, patient had the following side effects: arthralgia, dysstasia, pain (What is pain?), pain in extremity on May 14, 2004 from JAPAN Additional patient health information: Female patient , 50 years of age, was diagnosed with breast cancer recurrent, metastases to bone and. Quadramet dosage: 2170 Mbq, 1x/day, Intravenous. Patient was hospitalized.

4688256-1 | Metastases To Bone Marrow, Metastases To Lung, Neutropenia, Pyrexia
Adverse event was reported on Jun 09, 2005 by a Male patient taking Quadramet (View Usage) (Dosage: 89 Mci) was diagnosed with bladder cancer (What is bladder cancer?) and. Location: , 64 years of age, weighting 196.0 lb, Patient experienced the following unwanted or unexpected effects: metastases to bone marrow, metastases to lung, neutropenia, pyrexia. During the same period patient was treated with DURAGESIC 100 (View Duragesic-100 Review and Duragesic-100 Label ), ACTIQ (View Actiq Review and Actiq Label ).

4680255-9 | Condition Aggravated, Disease Progression, Osteolysis, Pain
on May 13, 2004 Female patient from , 53 years of age, was diagnosed with breast cancer recurrent, metastases to bone and was treated with Quadramet (View Usage). Patient had the following side effects: condition aggravated, disease progression, osteolysis, pain (What is pain?). Quadramet dosage: 1798.4 Mbq. 1 Dose Intravenous. Patient was hospitalized.

4680255-9 | Condition Aggravated, Disease Progression, Osteolysis, Pain
on May 13, 2004 Female patient from JAPAN , 53 years of age, was diagnosed with breast cancer recurrent, metastases to bone and was treated with Quadramet (View Usage). After Quadramet was administered, patient had the following side effects: condition aggravated, disease progression, osteolysis, pain (What is pain?). Quadramet dosage: 1798.4 Mbq. 1 Dose Intravenous. Patient was hospitalized.

4680209-2 | Back Pain, Condition Aggravated, Disseminated Intravascular Coagulation, Dyspnoea, Haemoglobin Decreased, Haemorrhage, Hip Fracture, Malignant Neoplasm Progression
Patient was taking Quadramet (View Usage). Patient experienced the following unwanted or unexpected effects: back pain (What is back pain?), condition aggravated, disseminated intravascular coagulation, dyspnoea, haemoglobin decreased, haemorrhage, hip fracture, malignant neoplasm progression on Mar 03, 2005 from Additional patient health information: Female patient , 61 years of age, weighting 216.1 lb, . Quadramet dosage: 18.5 Mbq. During the same period patient was treated with ANALGESICS (View Analgesics Review and Analgesics Label ). Patient was hospitalized and became disabled.

4680204-3 | Disease Progression, Paresis
Adverse event was reported on Dec 02, 2004 by a Male patient taking Quadramet (View Usage) (Dosage: 18.5 Mbq, Intravenous) was diagnosed with prostate cancer metastatic and. Location: , 77 years of age, weighting 154.3 lb, Patient had the following side effects: disease progression, paresis. During the same period patient was treated with ZOMETA (1 Dose) (View Zometa Review and Zometa Label ), BENALAPRIL (ENALAPRIL) (View Benalapril (enalapril) Review and Benalapril (enalapril) Label ), AMLODIPINE (View Amlodipine Review and Amlodipine Label ), CHLORTALIDONE (CHLORTALIDONE) (View Chlortalidone (chlortalidone) Review and Chlortalidone (chlortalidone) Label ), CARBASALATAE CALCIUM (CARBASALATAE CALCIUM) (View Carbasalatae Calcium (carbasalatae Calcium) Review and Carbasalatae Calcium (carbasalatae Calcium) Label ), GOSERELIN (GOSERELIN) (View Goserelin (goserelin) Review and Goserelin (goserelin) Label ). Patient was hospitalized.

4680203-1 | Anorexia, Arthralgia, Breast Cancer Metastatic, Condition Aggravated, Dysuria, Haematuria, Malignant Neoplasm Progression, Pain, Proteus Infection
on Mar 15, 2005 Female patient from , 72 years of age, weighting 85.98 lb, was diagnosed with metastases to bone and was treated with Quadramet (View Usage). After Quadramet was administered, patient had the following side effects: anorexia, arthralgia, breast cancer metastatic, condition aggravated, dysuria, haematuria, malignant neoplasm progression, pain (What is pain?), proteus infection. Quadramet dosage: 748 Mbq, 1x/day, Intravenous. During the same period patient was treated with AROMASIN (View Aromasin Review and Aromasin Label ), SOLETON (ZALTOPROFEN) (View Soleton (zaltoprofen) Review and Soleton (zaltoprofen) Label ), CONIEL (BENIDIPIEN HYDROCHLORIDE) (View Coniel (benidipien Hydrochloride) Review and Coniel (benidipien Hydrochloride) Label ), MUCOSTA (REBAMIPIDE) (View Mucosta (rebamipide) Review and Mucosta (rebamipide) Label ), AMOBAN (ZOPICLONE ) (View Amoban (zopiclone ) Review and Amoban (zopiclone ) Label ), PURSENNID (SENNOSIDE A+B, SENNOSIDE A+B CALCIUM) (View Pursennid (sennoside A+b, Sennoside A+b Calcium) Review and Pursennid (sennoside A+b, Sennoside A+b Calcium) Label ). Patient was hospitalized.

4680201-8 | Anorexia, Breast Cancer Metastatic, Condition Aggravated, Dysuria, Haematuria, Malignant Neoplasm Progression, Proteus Infection, Urinary Tract Infection
on Feb 15, 2005 Female patient from , 72 years of age, weighting 85.98 lb, was diagnosed with metastases to bone and was treated with Quadramet (View Usage). Patient experienced the following unwanted or unexpected effects: anorexia, breast cancer metastatic, condition aggravated, dysuria, haematuria, malignant neoplasm progression, proteus infection, urinary tract infection (What is urinary tract infection?). Quadramet dosage: 748mbq, 1 Dose, Intravenous. During the same period patient was treated with AROMASIN (View Aromasin Review and Aromasin Label ), SOLETON (ZALTOPROFEN) (View Soleton (zaltoprofen) Review and Soleton (zaltoprofen) Label ), CONIEL (BENIDIPINE HYDROCHLORIDE) (View Coniel (benidipine Hydrochloride) Review and Coniel (benidipine Hydrochloride) Label ), MUCOSTA (REBAMIPIDE) (View Mucosta (rebamipide) Review and Mucosta (rebamipide) Label ), AMOBRAN (ZOPICLONE) (View Amobran (zopiclone) Review and Amobran (zopiclone) Label ), PURSENNID (SENNOSIDE A+B, SENNOSIDE A+B CALCIUM) (View Pursennid (sennoside A+b, Sennoside A+b Calcium) Review and Pursennid (sennoside A+b, Sennoside A+b Calcium) Label ). Patient was hospitalized.

4680196-7 | Anorexia, Nausea
Patient was taking Quadramet (View Usage). Patient had the following side effects: anorexia, nausea (What is nausea?) on Dec 16, 2004 from Additional patient health information: Male patient , 66 years of age, was diagnosed with metastases to bone and. Quadramet dosage: . During the same period patient was treated with ZOMETA (View Zometa Review and Zometa Label ), HORMONES AND RELATED AGENTS (View Hormones And Related Agents Review and Hormones And Related Agents Label ). Patient was hospitalized.